{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:56:11Z","timestamp":1785862571645,"version":"3.56.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Real-world impact of device-aided therapy on quality of life (QoL) in people with Parkinson\u2019s remains unknown. This large, retrospective, observational study assessed QoL in people transitioning to device-aided therapy (deep brain stimulation or carbidopa-levodopa enteral suspension) vs. those continuing oral medications. Cohorts were matched based on clinical\/demographic characteristics and device-aided therapy eligibility. Primary and secondary outcomes included change from baseline (CFB) to month 12 in 39-item Parkinson\u2019s Disease Questionnaire (PDQ-39) and Unified Parkinson\u2019s Disease Rating Scale (UPDRS) scores, respectively. Of 608 people (oral therapy [\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009295]; device-aided therapy [\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009313]), most were male, White, and aged \u2265 60 years. Positive CFB to month 12 in PDQ-39 was significantly greater for device-aided therapy vs. oral therapy (\u20135.0 [95% CI, \u20135.9 to \u20134.2] vs. 0.9 [0.3\u20131.5];\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). UPDRS II-IV scores improved for the device-aided therapy group. People transitioning to device-aided therapy experienced clinically meaningful QoL improvements.\n                  <\/jats:p>","DOI":"10.1038\/s41531-025-01093-x","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T04:42:15Z","timestamp":1754887335000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Parkinson\u2019s disease quality of life at 12 months comparing invasive device-aided therapy with oral treatment"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9253-3899","authenticated-orcid":false,"given":"Adolfo","family":"Ramirez-Zamora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6247-9358","authenticated-orcid":false,"given":"Michael S.","family":"Okun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavnit","family":"Kukreja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,11]]},"reference":[{"key":"1093_CR1","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.2147\/NDT.S422717","volume":"19","author":"VA Constantin","year":"2023","unstructured":"Constantin, V. A., Sz\u00e1sz, J. A., Dulamea, A. O., Valkovic, P. & Kulisevsky, J. Impact of infusion therapies on quality of life in advanced Parkinson\u2019s disease. Neuropsychiatr. Dis. Treat. 19, 1959\u20131972 (2023).","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"1093_CR2","doi-asserted-by":"publisher","first-page":"670","DOI":"10.2174\/187152711797247885","volume":"10","author":"MA Cenci","year":"2011","unstructured":"Cenci, M. A., Ohlin, K. E. & Odin, P. Current options and future possibilities for the treatment of dyskinesia and motor fluctuations in Parkinson\u2019s disease. CNS Neurol. Disord. Drug Targets 10, 670\u2013684 (2011).","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"1093_CR3","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/S1474-4422(06)70521-X","volume":"5","author":"CW Olanow","year":"2006","unstructured":"Olanow, C. W., Obeso, J. A. & Stocchi, F. Continuous dopamine-receptor treatment of Parkinson\u2019s disease: scientific rationale and clinical implications. Lancet Neurol. 5, 677\u2013687 (2006).","journal-title":"Lancet Neurol."},{"key":"1093_CR4","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1212\/WNL.0b013e3181a1d44c","volume":"72","author":"CW Olanow","year":"2009","unstructured":"Olanow, C. W., Stern, M. B. & Sethi, K. The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology 72, S1\u2013136 (2009).","journal-title":"Neurology"},{"key":"1093_CR5","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1097\/RLU.0000000000001470","volume":"42","author":"A Bestetti","year":"2017","unstructured":"Bestetti, A., Capozza, A., Lacerenza, M., Manfredi, L. & Mancini, F. Delayed gastric emptying in advanced Parkinson disease: correlation with therapeutic doses. Clin. Nucl. Med 42, 83\u201387 (2017).","journal-title":"Clin. Nucl. Med"},{"key":"1093_CR6","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1002\/mds.22643","volume":"24","author":"P Barone","year":"2009","unstructured":"Barone, P. et al. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson\u2019s disease. Mov. Disord. 24, 1641\u20131649 (2009).","journal-title":"Mov. Disord."},{"key":"1093_CR7","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/mds.20279","volume":"20","author":"S Chapuis","year":"2005","unstructured":"Chapuis, S., Ouchchane, L., Metz, O., Gerbaud, L. & Durif, F. Impact of the motor complications of Parkinson\u2019s disease on the quality of life. Mov. Disord. 20, 224\u2013230 (2005).","journal-title":"Mov. Disord."},{"key":"1093_CR8","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1007\/s00702-013-0981-5","volume":"120","author":"KR Chaudhuri","year":"2013","unstructured":"Chaudhuri, K. R., Rizos, A. & Sethi, K. D. Motor and nonmotor complications in Parkinson's disease: an argument for continuous drug delivery?. J. Neural Transm. (Vienna) 120, 1305\u20131320 (2013).","journal-title":"J. Neural Transm. (Vienna)"},{"key":"1093_CR9","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jns.2009.08.053","volume":"289","author":"D Grosset","year":"2010","unstructured":"Grosset, D. Therapy adherence issues in Parkinson\u2019s disease. J. Neurol. Sci. 289, 115\u2013118 (2010).","journal-title":"J. Neurol. Sci."},{"key":"1093_CR10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s40263-014-0220-0","volume":"29","author":"N Malek","year":"2015","unstructured":"Malek, N. & Grosset, D. G. Medication adherence in patients with Parkinson\u2019s disease. CNS Drugs 29, 47\u201353 (2015).","journal-title":"CNS Drugs"},{"key":"1093_CR11","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1007\/s40263-022-00963-9","volume":"36","author":"A Antonini","year":"2022","unstructured":"Antonini, A. et al. Comparative effectiveness of device-aided therapies on quality of life and off-time in advanced Parkinson\u2019s disease: a systematic review and Bayesian network meta-analysis. CNS Drugs 36, 1269\u20131283 (2022).","journal-title":"CNS Drugs"},{"key":"1093_CR12","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3233\/JPD-161042","volume":"7","author":"AA Othman","year":"2017","unstructured":"Othman, A. A., Rosebraugh, M., Chatamra, K., Locke, C. & Dutta, S. Levodopa-carbidopa intestinal gel pharmacokinetics: lower variability than oral levodopa-carbidopa. J. Parkinsons Dis. 7, 275\u2013278 (2017).","journal-title":"J. Parkinsons Dis."},{"key":"1093_CR13","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1474-4422(13)70293-X","volume":"13","author":"CW Olanow","year":"2014","unstructured":"Olanow, C. W. et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson\u2019s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 13, 141\u2013149 (2014).","journal-title":"Lancet Neurol."},{"key":"1093_CR14","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1001\/jamaneurol.2017.4321","volume":"75","author":"A Ramirez-Zamora","year":"2018","unstructured":"Ramirez-Zamora, A. & Ostrem, J. L. Globus pallidus interna or subthalamic nucleus deep brain stimulation for Parkinson disease: a review. JAMA Neurol. 75, 367\u2013372 (2018).","journal-title":"JAMA Neurol."},{"key":"1093_CR15","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1002\/mds.29066","volume":"37","author":"G Deuschl","year":"2022","unstructured":"Deuschl, G. et al. European Academy of Neurology\/Movement Disorder Society-European section guideline on the treatment of Parkinson\u2019s disease: I. invasive therapies. Mov. Disord. 37, 1360\u20131374 (2022).","journal-title":"Mov. Disord."},{"key":"1093_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2023.105514","volume":"116","author":"HH Fernandez","year":"2023","unstructured":"Fernandez, H. H. et al. Healthcare resource utilization and device-aided therapy discussions with eligible patients across the Parkinson\u2019s disease continuum: revelations from the MANAGE-PD validation cohort. Parkinsonism Relat. Disord. 116, 105514 (2023).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1093_CR17","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/ane.13648","volume":"146","author":"A Fasano","year":"2022","unstructured":"Fasano, A. et al. Intercountry comparisons of advanced Parkinson\u2019s disease symptoms and management: analysis from the OBSERVE-PD observational study. Acta Neurol. Scand. 146, 167\u2013176 (2022).","journal-title":"Acta Neurol. Scand."},{"key":"1093_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000455863","volume":"48","author":"K Horv\u00e1th","year":"2017","unstructured":"Horv\u00e1th, K. et al. Changes in quality of life in Parkinson\u2019s disease: how large must they be to be relevant?. Neuroepidemiology 48, 1\u20138 (2017).","journal-title":"Neuroepidemiology"},{"key":"1093_CR19","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1001\/jama.2008.929","volume":"301","author":"FM Weaver","year":"2009","unstructured":"Weaver, F. M. et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA 301, 63\u201373 (2009).","journal-title":"JAMA"},{"key":"1093_CR20","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S1474-4422(10)70093-4","volume":"9","author":"A Williams","year":"2010","unstructured":"Williams, A. et al. Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson\u2019s disease (PD SURG trial): a randomised, open-label trial. Lancet Neurol. 9, 581\u2013591 (2010).","journal-title":"Lancet Neurol."},{"key":"1093_CR21","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1002\/mds.28703","volume":"36","author":"E Freire-Alvarez","year":"2021","unstructured":"Freire-Alvarez, E. et al. Levodopa-carbidopa intestinal gel reduces dyskinesia in Parkinson\u2019s disease in a randomized trial. Mov. Disord. 36, 2615\u20132623 (2021).","journal-title":"Mov. Disord."},{"key":"1093_CR22","doi-asserted-by":"publisher","first-page":"769","DOI":"10.3233\/JPD-225105","volume":"13","author":"KR Chaudhuri","year":"2023","unstructured":"Chaudhuri, K. R. et al. Levodopa carbidopa intestinal gel in advanced Parkinson\u2019s disease: DUOGLOBE final 3-year results. J. Parkinsons Dis. 13, 769\u2013783 (2023).","journal-title":"J. Parkinsons Dis."},{"key":"1093_CR23","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/j.1468-1331.2004.00804.x","volume":"11","author":"E Lezcano","year":"2004","unstructured":"Lezcano, E. et al. Improvement in quality of life in patients with advanced Parkinson\u2019s disease following bilateral deep-brain stimulation in subthalamic nucleus. Eur. J. Neurol. 11, 451\u2013454 (2004).","journal-title":"Eur. J. Neurol."},{"key":"1093_CR24","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41531-021-00223-5","volume":"7","author":"ML Lachenmayer","year":"2021","unstructured":"Lachenmayer, M. L. et al. Subthalamic and pallidal deep brain stimulation for Parkinson\u2019s disease-meta-analysis of outcomes. NPJ Parkinsons Dis. 7, 77 (2021).","journal-title":"NPJ Parkinsons Dis."},{"key":"1093_CR25","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1007\/s10072-021-05106-4","volume":"42","author":"L Marsili","year":"2021","unstructured":"Marsili, L., Bologna, M., Miyasaki, J. M. & Colosimo, C. Device-aided therapies for advanced Parkinson disease: insights from an international survey. Neurol. Sci. 42, 2961\u20132964 (2021).","journal-title":"Neurol. Sci."},{"key":"1093_CR26","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1205158","volume":"368","author":"WM Schuepbach","year":"2013","unstructured":"Schuepbach, W. M. et al. Neurostimulation for Parkinson\u2019s disease with early motor complications. N. Engl. J. Med 368, 610\u2013622 (2013).","journal-title":"N. Engl. J. Med"},{"key":"1093_CR27","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s40266-018-0599-2","volume":"35","author":"M Fabbri","year":"2018","unstructured":"Fabbri, M., Rosa, M. M. & Ferreira, J. J. Adjunctive therapies in Parkinson\u2019s disease: how to choose the best treatment strategy approach. Drugs Aging 35, 1041\u20131054 (2018).","journal-title":"Drugs Aging"},{"key":"1093_CR28","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1007\/s00702-023-02680-z","volume":"130","author":"F Borove\u010dki","year":"2023","unstructured":"Borove\u010dki, F. et al. Are Parkinson\u2019s disease patients referred too late for device-aided therapies and how can better informed and earlier referrals be encouraged?. J. Neural Transm. (Vienna) 130, 1405\u20131409 (2023).","journal-title":"J. Neural Transm. (Vienna)"},{"key":"1093_CR29","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.parkreldis.2021.10.009","volume":"92","author":"A Antonini","year":"2021","unstructured":"Antonini, A. et al. Validation and clinical value of the MANAGE-PD tool: a clinician-reported tool to identify Parkinson\u2019s disease patients inadequately controlled on oral medications. Parkinsonism Relat. Disord. 92, 59\u201366 (2021).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1093_CR30","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1080\/03007995.2018.1502165","volume":"34","author":"A Antonini","year":"2018","unstructured":"Antonini, A. et al. Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson\u2019s disease: a multi-country Delphi-panel approach. Curr. Med Res Opin. 34, 2063\u20132073 (2018).","journal-title":"Curr. Med Res Opin."},{"key":"1093_CR31","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1007\/s00702-023-02668-9","volume":"130","author":"M Auffret","year":"2023","unstructured":"Auffret, M., Weiss, D., Stocchi, F., V\u00e9rin, M. & Jost, W. H. Access to device-aided therapies in advanced Parkinson\u2019s disease: navigating clinician biases, patient preference, and prognostic uncertainty. J. Neural Transm. (Vienna) 130, 1411\u20131432 (2023).","journal-title":"J. Neural Transm. (Vienna)"},{"key":"1093_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.605959","volume":"12","author":"S Das","year":"2021","unstructured":"Das, S. et al. Capturing initial understanding and impressions of surgical therapy for Parkinson\u2019s disease. Front Neurol. 12, 605959 (2021).","journal-title":"Front Neurol."},{"key":"1093_CR33","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1007\/s40120-023-00533-1","volume":"12","author":"J Aldred","year":"2023","unstructured":"Aldred, J. et al. Continuous subcutaneous foslevodopa\/foscarbidopa in Parkinson\u2019s disease: safety and efficacy results from a 12-month, single-arm, open-label, phase 3 study. Neurol. Ther. 12, 1937\u20131958 (2023).","journal-title":"Neurol. Ther."},{"key":"1093_CR34","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/S1474-4422(22)00400-8","volume":"21","author":"MJ Soileau","year":"2022","unstructured":"Soileau, M. J. et al. Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson\u2019s disease: a randomised, double-blind, active-controlled, phase 3 trial. Lancet Neurol. 21, 1099\u20131109 (2022).","journal-title":"Lancet Neurol."},{"key":"1093_CR35","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.parkreldis.2020.12.024","volume":"83","author":"R Katzenschlager","year":"2021","unstructured":"Katzenschlager, R. et al. Long-term safety and efficacy of apomorphine infusion in Parkinson\u2019s disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO study. Parkinsonism Relat. Disord. 83, 79\u201385 (2021).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1093_CR36","doi-asserted-by":"publisher","first-page":"10","DOI":"10.18773\/austprescr.2025.003","volume":"48","author":"N Mouchaileh","year":"2025","unstructured":"Mouchaileh, N. & Cameron, J. Device-assisted therapies for Parkinson disease. Aust. Prescr. 48, 10\u201317 (2025).","journal-title":"Aust. Prescr."},{"key":"1093_CR37","unstructured":"Fahn, S. & Elton R. L.; UPDRS Program Members. In Recent Developments in Parkinson\u2019s Disease, Vol. 2. 153\u2013163, 293\u2013304 (Macmillan Healthcare Information, 1987)."},{"key":"1093_CR38","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/BF02260863","volume":"4","author":"V Peto","year":"1995","unstructured":"Peto, V., Jenkinson, C., Fitzpatrick, R. & Greenhall, R. The development and validation of a short measure of functioning and well being for individuals with Parkinson\u2019s disease. Qual. Life Res.4, 241\u2013248 (1995).","journal-title":"Qual. Life Res."},{"key":"1093_CR39","unstructured":"Schwab, R. S. & England, A. C. In Third Symposium on Parkinson\u2019s Disease, Royal College of Surgeons in Edinburgh 152\u2013157 (E&S, Livingstone Ltd, 1968)."}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01093-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01093-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01093-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T12:09:23Z","timestamp":1778069363000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01093-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,11]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1093"],"URL":"https:\/\/doi.org\/10.1038\/s41531-025-01093-x","relation":{},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,11]]},"assertion":[{"value":"30 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.R-Z. has received research support from the Parkinson\u2019s Foundation and consulting honoraria from Boston Scientific, Cerevel, Medtronic, Novo Nordisk, Rho, and Signant, but declares no non-financial competing interests. M.S.O. serves as medical advisor to the Parkinson\u2019s Foundation and has received research grants from the NIH, Parkinson\u2019s Foundation, Michael J. Fox Foundation, Parkinson Alliance, Smallwood Foundation, Bachmann-Strauss Foundation, Tourette Syndrome Association, and the UF Foundation. His research is supported by grants R01 NS131342 NIH R01 NR014852, R01NS096008, UH3NS119844, U01NS119562. He is the principal investigator of the NIH training grant R25NS108939 and has received royalties for publications with Hachette Book Group, Demos, Manson, Amazon, Smashwords, Books4Persons, Perseus, Robert Rose, Oxford University Press, and Cambridge University Press (for movement disorders books). He is an associate editor for the\n                      New England Journal of Medicine Journal Watch-Neurology\n                      and\n                      JAMA Neurology\n                      . He has participated in continuing medical education and educational activities on movement disorders sponsored by WebMD\/Medscape, RMEI Medical Education, American Academy of Neurology, Movement Disorders Society, Mediflix, and Vanderbilt University. The institution and not Dr. Okun receives grants from industry. He has participated as a site principal investigator and\/or co-investigator for several NIH, UF Foundation, and industry-sponsored trials over the years but has not received honoraria. Research projects at the University of Florida receive device and drug donations. He declares no non-financial competing interests. P.K. is an employee of AbbVie and may hold AbbVie stock and\/or stock options but declares no non-financial competing interests. W.H. has received research support from the Parkinson\u2019s Foundation, American Brain Foundation, and Tyler\u2019s Hope for a Dystonia Cure and declares no non-financial competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"235"}}